Difference between revisions of "Blastic plasmacytoid dendritic cell neoplasm"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
|||
| Line 24: | Line 24: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[http://www.bloodjournal.org/content/124/3/385.long Frankel et al. 2014] | + | |[http://www.bloodjournal.org/content/124/3/385.long Frankel et al. 2014 (STU 012013-061)] |
| style="background-color:#ffffbe" |Phase I/II, <20 pts | | style="background-color:#ffffbe" |Phase I/II, <20 pts | ||
| + | |- | ||
| + | |[https://www.nejm.org/doi/full/10.1056/NEJMoa1815105 Pemmaraju et al. 2019 (STML-401-0114)] | ||
| + | | style="background-color:#91cf61" |Phase I/II | ||
|- | |- | ||
|} | |} | ||
| Line 34: | Line 37: | ||
===References=== | ===References=== | ||
| − | # Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. [http://www.bloodjournal.org/content/124/3/385.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24859366 PubMed] | + | # '''STU 012013-061:''' Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. [http://www.bloodjournal.org/content/124/3/385.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24859366 PubMed] |
| + | # '''STML-401-0114:''' Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. [https://www.nejm.org/doi/full/10.1056/NEJMoa1815105 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/31018069 PubMed] | ||
[[Category:Blastic plasmacytoid dendritic cell neoplasm regimens]] | [[Category:Blastic plasmacytoid dendritic cell neoplasm regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Acute leukemias]] | [[Category:Acute leukemias]] | ||
Revision as of 18:49, 13 June 2019
| Section editor | |
|---|---|
 |
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO  mwschoen
|
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tagraxofusp monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Frankel et al. 2014 (STU 012013-061) | Phase I/II, <20 pts |
| Pemmaraju et al. 2019 (STML-401-0114) | Phase I/II |
Chemotherapy
- Tagraxofusp (Elzonris) 12 mcg/kg IV over 15 minutes once per day on days 1 to 5
21-day cycles
References
- STU 012013-061: Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article PubMed
- STML-401-0114: Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. link to original article contains verified protocol PubMed